Case number# PHHY2015SK060577, is an initial spontaneous report received from a physician via pharmaceutical 
company (Biogen Inc.) via email on 15 May 2015, with a subsequent follow up report received from a physician via 
pharmaceutical company (Biogen Inc.) on 14 Oct 2015.
This report refers to a 38 year old female patient. Medical history was not reported. No concomitant medication was
reported. The patient was on Tysabri before Gilenya as the case was received from Biogen.
The patient received Gilenya (fingolimod) capsule for an unknown indication from an unspecified therapy date, dose
and route.
On an unknown date, the patient had suspected progressive multifocal leukoencephalopathy (PML). The patient 
was on Gilenya in Oct 2015. Action taken with Gilenya was unknown.
Print Time: 07-JUN-2016 03:01 PM If a field is blank, there is no data for that field Page 470 of 549
FDA - Adverse Event Reporting System (FAERS) 
FOIA Case Report Information
The outcome of the event progressive multifocal leukoencephalopathy was not reported. The seriousness and 
causality of the event were not reported by the physician. Seriousness assessment of (Progressive multifocal 
leukoencephalopathy) was upgraded based on the NVS-IME list.
Novartis currently does not have the contact details of reporting physician from Biogen. Novartis is in contact with 
Biogen to get the contact details of reporting physician and will do follow up of the case accordingly.
Follow up report received from a physician via pharmaceutical company (Biogen Inc.) on 14 Oct 2015: Updated 
contact details of physician, patient's demographics (initials and age) and therapy details of Gilenya.